Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.
Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.Show MeSH
Related in: MedlinePlus
Mentions: As shown in Figure 2 and Table 2, the median PFS for patients receiving bevacizumab-based treatment was 8.5 months in group I and 6.4 months in group II (P = 0.023). One-year PFS rates were 24% (95% CI 15–36%) in group I, and 13% (95% CI 7–25%) in group II (Table 2, Fig. 2a). The hazard ratio (HR) of group II versus group I was 1.47 (95% CI, 1.05–2.05). This HR was virtually unchanged if adjusted for T and N (HR, 1.47; 95% CI, 1.04–2.09). Figure 2(b) depicts the hazard of progression at various baseline serum CEA levels, relative to the median level of 26.8 ng/mL. This analysis indicates the almost linear dependency of the progression risk on the baseline serum CEA level. Compared to the median level of 26.8 ng/mL, patients with CEA levels of >69 ng/mL were at a significantly elevated risk for progression. In contrast, the progression risk appeared to be lower for patients with CEA levels lower than 26.8 ng/mL, but a significance level was not reached.
Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.